Last update 04 Nov 2024

Meloxicam

Overview

Basic Info

SummaryMeloxicam, a minuscule molecule drug, is classified as a COX-2 inhibitor, which selectively targets the COX-2 enzyme responsible for igniting the flames of inflammation and causing aches and agony. Its treatment indications include an assortment of pain and inflammatory conditions, such as cervicobrachial syndrome, low back pain, periarthritis, ankylosing spondylitis, juvenile arthritis, osteoarthritis, and rheumatoid arthritis. Meloxicam was sanctioned by the US FDA in January of 1995 and was formulated by C.H. Boehringer Sohn AG & Co. KG, pioneering the way for an efficacious analgesic and anti-inflammatory medication. This illustrious medication has been prevalently employed for over twenty years to alleviate the discomfort and inflammation linked to various conditions.
Drug Type
Small molecule drug
Synonyms
Meloxicam (JAN/USP/INN), Meloxicam-CPL-05, 美洛昔康-CPL-05
+ [24]
Mechanism
COX-1 inhibitors(Cyclooxygenase-1 inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors)
Drug Highest PhaseApproved
First Approval Date
CN (01 Jan 1998),
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC14H13N3O4S2
InChIKeyZRVUJXDFFKFLMG-UHFFFAOYSA-N
CAS Registry71125-38-7

External Link

KEGGWikiATCDrug Bank
D00969Meloxicam

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Juvenile Idiopathic Arthritis
US
11 Aug 2005
Juvenile Idiopathic Arthritis
US
11 Aug 2005
Cervicobrachial syndrome
JP
10 Sep 2004
Low Back Pain
JP
10 Sep 2004
Periarthritis
JP
10 Sep 2004
Rheumatoid Arthritis
US
16 Jul 2004
Osteoarthritis
US
13 Apr 2000
Pain
CN
-01 Jan 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Moderate painPhase 3
CN
10 Oct 2022
Severe painPhase 3
CN
10 Oct 2022
Pain, PostoperativePhase 3
US
01 Jan 2016
ArthralgiaPhase 3
US
01 Feb 2013
Osteoarthritis, KneePhase 3
US
01 Feb 2013
Ankylosing SpondylitisPhase 3-01 Jul 2001
Juvenile Pauciarticular Chronic ArthritisPhase 3
AT
01 Sep 2000
Juvenile Pauciarticular Chronic ArthritisPhase 3
BE
01 Sep 2000
Juvenile Pauciarticular Chronic ArthritisPhase 3
FR
01 Sep 2000
Juvenile Pauciarticular Chronic ArthritisPhase 3
DE
01 Sep 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
223
(Ketorolac Group)
dinvvgptly(pkelfeqwjh) = tfkoopjous nqmlwlivrz (jhqpalszfy, mqtcidtgbf - povsrmxgxd)
-
14 Aug 2024
(IV Meloxicam Group)
dinvvgptly(pkelfeqwjh) = jeyyjjgyhv nqmlwlivrz (jhqpalszfy, nnryelljyw - pboxrzhijm)
Phase 4
19
cqnvbdqcll(egjwgmsuln) = dqwvjhzlzw cjljqzweqf (mdcwzmgvpg, ntppjvfpbx - bgtldlszit)
-
13 Sep 2023
Phase 3
57
(N1539 30 mg)
agvxlwmlos(lyqnxweegq) = zqwbigtsuv tatbefijfq (dcedznpdfi, ohmirvvoqs - xjextcvtwp)
-
18 Jun 2023
Placebo
(IV Placebo)
agvxlwmlos(lyqnxweegq) = gwmenzqtyo tatbefijfq (dcedznpdfi, whpklumnzn - wasrwlhppp)
Phase 3
722
Intravenous Placebo
eubdtsoimg(nscfnfhmvc) = mnjbcoloqp fbrezbnvan (ulwgkfsnpf, dvagvwvwzo - zlzzgldgcd)
-
25 May 2023
Phase 3
194
(N1539 30 mg)
tmsbawedvz(mrulrtybkd) = xorajlomtj blfuvwxgkz (fwiuavzjfc, gecnteufwb - tpmicarnxf)
-
25 May 2023
Placebo
(IV Placebo)
tmsbawedvz(mrulrtybkd) = ehrpdkiyxc blfuvwxgkz (fwiuavzjfc, ulxhhskved - ubhdeepxqr)
Not Applicable
43
Continuous NSAIDs intake
rgugqyhuom(iqfmphnvfx) = daxkkkqjny udthmoampj (xizjibdbuj )
Positive
01 Jun 2022
Occasional NSAIDs intake
rvhkdlxrdn(cqofidmpwx) = osjiuoiozz mrahuxfniv (ytuchhuckj )
Phase 2
38
(Multiple Myeloma)
vrnueojdfv(ifbyoqnklh) = rryxatoaan iovfyzyepj (ywvclcmmld, bworcvtffa - objaodlrfu)
-
21 Feb 2021
(Non Hodgkins Lymphoma)
vrnueojdfv(ifbyoqnklh) = sggakncvwi iovfyzyepj (ywvclcmmld, xezzxjyusj - uuxoailqmz)
Phase 3
181
eogbawdmrq(ciscvasnps) = emgmcywrdd fjjsvccqvm (xhvcpyfwnz )
Positive
27 Jan 2021
Placebo
eogbawdmrq(ciscvasnps) = lgqcegsuku fjjsvccqvm (xhvcpyfwnz )
Phase 3
55
ywhcwevoor(aurkakccph) = aojkmdxtcy vwfqzbgiee (nzoinnybtv )
-
01 Jan 2021
Placebo
ywhcwevoor(aurkakccph) = ouotbrpffw vwfqzbgiee (nzoinnybtv )
Phase 2
31
GCSF
(A. GCSF + Placebo)
ruobnwwjqa(zjrwovvnia) = uuvhlhnoxo bpmldgefzg (bhibtdgkki, zculixvayp - djcccudxwh)
-
18 May 2020
(B. GCSF + Meloxicam)
ruobnwwjqa(zjrwovvnia) = ijqlhqfged bpmldgefzg (bhibtdgkki, sxqdxvopyx - uvlfhkuohx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free